Adjuvant treatment for gastric cancer: too much is not enough
Mené au Japon sur 1 495 patients atteints d'un cancer localement avancé de l'estomac, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans maladie, et la toxicité de deux séquences de chimiothérapie (paclitaxel puis tégafur et uracile ou paclitaxel puis S-1) en traitement adjuvant
Gastric cancer is the fourth most common cancer and the second leading cause of cancer-related deaths worldwide. Regions with high incidence, including Japan and South Korea, have achieved success in three areas: screening and early-stage detection; defining how radical surgical resection should be; and development of postoperative adjuvant treatment. Japanese surgeons established the global standard of surgical resection: D2 lymphadenectomy. Although the first positive trial for adjuvant treatm ...
The Lancet Oncology , commentaire, 2013